Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive KarXT for Treatment of Bipolar I Mania
2025-521845-26-00Phase 3Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in bipolar I disorder comparing KarXT adjunctive arm with Placebo adjunctive arm (2 arms). Primary endpoint: Change from baseline in Young Mania Rating Scale (YMRS) score at Week 5. Planned start Mar 2026; status: authorised.
02
Drugs
xanomeline
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on 2025-521845-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521845-26-00.